Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.77 |
| ▸ | HPGD | P15428 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.61 |
| ▸ | MEN1 | O00255 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24209696 | 0.88 | NPSR1 (0.67) | NPSR1HPGDKMT2AMEN1ALDH1A1 | |
| SCHEMBL24210094 | 0.87 | NPSR1 (1.00) | NPSR1HPGDKMT2AMEN1ALDH1A1 | |
| SCHEMBL24209778 | 0.85 | NPSR1 (0.67) | NPSR1HPGDKMT2AMEN1ALDH1A1 | |
| SCHEMBL24210088 | 0.84 | KMT2A (0.83) | NPSR1HPGDKMT2AMEN1ALDH1A1 | |
| SCHEMBL24209779 | 0.84 | KMT2A (0.76) | NPSR1HPGDKMT2AMEN1ALDH1A1 | |
| SCHEMBL24209697 | 0.84 | ALDH1A1 (0.82) | NPSR1KMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL24209777 | 0.82 | NPSR1 (0.83) | NPSR1HPGDKMT2AMEN1ALDH1A1 | |
| SCHEMBL24209692 | 0.82 | LMNA (0.83) | NPSR1HPGDKMT2AMEN1ALDH1A1 | |
| SCHEMBL24210195 | 0.81 | KMT2A (0.73) | NPSR1HPGDKMT2AMEN1ALDH1A1 | |
| SCHEMBL24019617 | 0.81 | NPSR1 (0.71) | NPSR1HPGDKMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220016080-A1 | COMPOUNDS THAT SELECTIVELY AND EFFECTIVELY INHIBIT HAKAI-MEDIATED UBIQUITINATION, AS ANTI-CANCER DRUGS | FUND PROFESOR NOVOA SANTOS (ES) | 2022-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220016080-A1 | COMPOUNDS THAT SELECTIVELY AND EFFECTIVELY INHIBIT HAKAI-MEDIATED UBIQUITINATION, AS ANTI-CANCER DRUGS | CHUK, HIPK3, HIPK1 | NPSR1 4502/4885HPGD 1570/4885KMT2A 2532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.